Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (269)	9/24/2002 7:15:08 PM
From: Miljenko Zuanic	Respond to of 1840

Thanks Peter, Rick. Call was based on definite sign of the activity as monotherapy, when magnitude (time frame) of this benefit is hard to predict and measure (+80% pts died in few months, God help them). Yes, IMCL disease is/was terrible for whole sector. Only one need to differentiate human factors from real word drug efficacy. For instance EGF blockage may help for while in H&N cancer, but this is SC carcinoma (high growth rate) and single punch is worthless. Miljenko

To: scaram(o)uche who wrote (269)	9/25/2002 1:40:08 AM
From: russet	Read Replies (1) \| Respond to of 1840

More head and neck??,...as for the body gene gun,...good thing mice are not an endangered species (ggggggg) Dr. Burian Presents Data From 12 Primary Head and Neck Cancer Patients Treated With Genetronics' Electroporation Therapy SAN DIEGO, Sept. 24 /CNW/ -- Genetronics Biomedical Corporation, San Diego, (Amex: GEB; Toronto) announced that Dr. Martin Burian of the University of Vienna, presented an abstract at the American Academy of Otolaryngology - Head and Neck Surgery Foundation, Inc. annual meeting today in San Diego, California. The abstract, entitled "Electroporation Therapy in Head and Neck Cancer," gives an overview of a study in which 12 patients diagnosed with primary head and neck cancer were treated with Genetronics' proprietary Electroporation Therapy (EPT) system. Four weeks after the treatment, the treated area and a save margin were excised and analyzed. In 10 out of the 12 patients there was no evidence of disease in the excised tissue, demonstrating a complete response rate of 83% in the patients treated. The conclusion of the abstract was that, "EPT seems to serve as an interesting alternative in the treatment of head and neck cancer." About Genetronics Genetronics Biomedical Corporation is the world leader in electroporation therapy with 216 patents issued, allowed, or pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic genes or vaccines using electroporation. More information can be obtained at http://www.genetronics.com Edit,...the website is still under construction (gggggg) For further information: investors, Clarke Galvin or Karl Cahill of Genetronics Biomedical Corporation, +1-858-597-6006 /Web site: genetronics.com